Campaign success - Duodopa is approved in Scotland!
People with advanced Parkinson's in Scotland will now be able to access the innovative treatment Duodopa more easily, after it was approved by the Scottish Medicines Consortium (SMC).
Parkinson's UK campaigned to overturn a previous SMC ruling on Duodopa, which left people facing treatment delays and postcode lotteries.
Controlling Parkinson's symptoms
Duodopa can help to control the symptoms of advanced Parkinson's when all other treatments have stopped working.
It can have a transformative effect on people – and can mean the difference between someone using a wheelchair, barely able to lift their head, and being able to walk around independently.
We worked with families affected by advanced Parkinson's to raise awareness of the issues that they faced.
Their courage enabled us to secure extensive media coverage and make a strong case to Scottish Government and SMC.
David and Fiona Taylor from Edinburgh generously shared their story. David said:
"My Parkinson's symptoms were so extreme that life was unbearable for me and my wife, but it still took nearly a year for my consultant to persuade the NHS Board to fund Duodopa.
"Before I started on Duodopa, I was taking tablets every 90 minutes, but they couldn't control my agonising cramps and violent involuntary movements.
"I couldn't sleep, and my wife was up eight times a night to help me. She was starting not to cope."
Duodopa can transform lives
Katherine Crawford, Scotland Director at Parkinson's UK, said:
"As David's story shows, Duodopa can transform lives. It's only suitable for a small number of people, and it's not a cure, but it can have a huge impact.
"Parkinson's UK is committed to finding better treatments and a cure for Parkinson's, and it's vital that people with Parkinson's have access to world-class treatments in Scotland."
Access around the UK
Duodopa is now available for routine prescription in England and Scotland. People in Wales and Northern Ireland are able to access Duodopa on a case by case basis.
You can help us secure better access to treatments by joining our Campaigns Network.